Protocols
2 protocol(s) meet the specified criteria
Drug: Durvalumab
Protocol No.TitleStatus
LCCC1621Multimodality Therapy with induction Carboplatin/nab-Paclitaxel/Durvalumab followed by surgical resection followed by risk-adapted adjuvant therapy for the treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Open
LCCC1725A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab together with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Open